Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Videos|March 22, 2021
Trauma: The Narrative That Takes Control
Author(s)Molly Ansari, PhD, LCPC, ATR-BC
Victims can get caught up in blaming themselves for their traumatic event...
Advertisement
Molly Ansari, PhD, LCPC, ATR-BC, talks about the narrative that can take over victim's perception of a traumatic event in the first part of her 2-video series.
Dr Ansari is an assistant professor at
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
4
Sabirnetug Misses Primary Endpoint in Phase 2 Alzheimer Disease Trial
5